Sources of Volunteer's Perception and Decision to Participate in the Prime-Boost HIV Vaccine Trial

  • เฉวตสรร นามวาท Bureau of Epidemiology
  • นคร เปรมศรี Bureau of HIV/AIDS, TB, and STD
  • ศุภชัย ฤกษ์งาม Deptatrment of Disease Control
  • จิรศักดิ์ คำบุญเรือง Deptatrment of Disease Control
  • ประยูร กุนาศล Deptatrment of Disease Control
  • จรณิต แก้วกังวาล Faculty of Tropical Medicine
  • Michael Benenson Armed Forces Research Institute of Medical Sciences
  • Robert Paris Armed Forces Research Institute of Medical Sciences
Keywords: HIV, vaccine trail, decision to participate, Volunteers


The world's largest preventive HIV vaccine trial enrolled 16,402 volunteers between September 2003 to December 2005 in Chon Buri and Rayong Provinces. Information sources that help potential volunteers understand the trial and enable them to voluntarily decide to participate in the project are keys for success. This study used a standardized questionnaire volunteers provided responses about the source from where they received information about the study and that influenced them to join the study. When full recruitment was achieved in December 2005, the sources that influenced and inspired volunteers to voluntarily join the trial were analyzed. The proportions of sources identified at three time points were compared. It was found that overall sources of perception were derived from "other enrolled volunteers" (55.6%), "local health staff" (32.6%), and "recruitment team" (21.9%). Over time the proportion of "enrolled volunteers" significantly increased from 40.2% to 66.6% (p<0.001), in contrast the "recruitment team" as a source decreased from 25.6% to 18.9% (p<0.001). The most cited sources of information leading to decision making, were "local health staff"(35.6%), "screening video" (26.9%), and "other enrolled volunteers" (22.0%). Conclusion: This data demonstrates that "Word of Mouth" from enrolled volunteers might be a powerful invisible force for recruitment.


Download data is not yet available.


1. S Rerks-Ngarm, AE. Brown, C Khamboonruang, P Thongcharoen and P Kunasol. HIV/AIDS preventive vaccine 'prime-boost' phase III trial: foundations and initial lessons learned from Thailand. AIDS 2006, 20:1471-1479.

2. ศุภชัย ฤกษ์งาม เฉวตสรร นามวาท นคร เปรมศรี ประยูร กุนาศล จิรศักดิ์ คำบุญเรือง ประเสริฐ ทองเจริญ. 18 พฤษภาคม วันวัคซีนเอดส์โลก. รายงานการเฝ้าระวังทางระบาดวิทยาประจำสัปดาห์. 2551;39 : 325-7.
3. Turner CF, Sheon AR. Behavioral studies relevant to vaccine trial preparation: an introduction. AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S273-6.

4. Newman PA, Duan N, Rudy ET, Anton PA. Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come? AIDS Patient Care STDS. 2004 Dec;18(12):691-701.

5. Gray K, Legg K, Sharp A, Mackie N, Olarinde F, De Souza C, Weber J, Peters B. Participation in two phase II prophylactic HIV vaccine trials in the UK. Vaccine. 2008 Jun 2;26(23): 2919-24. Epub 2008 Apr 9.

6. Swartz L, Kagee A. Community participation in AIDS vaccine trials: empowerment or science? Sci Med. 2006 Sep;63(5):1143-6. Epub 2006 May 16.

7. Kresge KJ. Enrolling teens in trials. Researchers consider the special circumstances of AIDS vaccine clinical trials among adolescents. IAVI Rep. 2006 Sep-Oct;10(4):11-14.

8. Swartz L, Kagee A. Community participation in AIDS vaccine trials: empowerment or science? Soc Sci Med. 2006 Sep;63(5):1143-6. Epub 2006 May 16.
Original Article